Yip Wang-Hin, Mingi Chan-Liao, Ooi Seng-Jin, Chen Shui-Cheng, Chiang Yung-Yuan
Department ofAnesthesiology, Jen-Ai Hospital, Tali, Taichung, Taiwan, ROC.
Acta Anaesthesiol Taiwan. 2004 Sep;42(3):147-51.
Malignant hyperthermia (MH) is a hypermetabolic disorder with high mortality. Intravenous administration of dantrolene is the specific treatment. However, the only means to lower mortality rate are early detection and suitable treatment. Therefore, properly monitoring and handy availability of dantrolene are essential to lower the mortality of MH. This study was designed to evaluate the capabilities in prevention and treatment of MH of the hospitals in Taiwan.
There were 102 certified training hospitals (including medical centers and regional hospitals) in Taiwan selected for this study. A questionnaire was designed to evaluate the capabilities of these hospitals in dealing with prevention and treatment of MH.
A total of 66 copies of the questionnaire were returned, which gave a response rate of 64.7%. The results of the survey are as follows: Succinylcholine was frequently used for induction in 92% of the hospitals investigated. For monitoring during general anesthesia, pulse oximeter was routinely used in 66(100%) hospitals, and ETCO2 monitor in 51 (77.3%) hospitals but continuous body temperature was routinely monitored only in 13 (19.7%) hospitals. Six or more vials of dantrolene were stored and available for immediate use in 23 (34.9%) hospitals and the rest of 43 (65.1%) hospitals did not have any stock of dantrolene at all. Of these 43 hospitals, 25 (58.1%) relied on other hospitals to supply dantrolene and the time required to obtain dantrolene from other hospitals was 70.7 +/- 34.7 min. There were 21 cases who sustained MH in 17 (25.8%) hospitals in the past ten years, of whom 15 were resuscitated successfully and 6 died, thus giving a mortality rate of 28.6%.
This study has revealed that in some hospitals in Taiwan intraoperatively (anesthetic) monitoring is inadequate and there is no stockpile of dantrolene for immediate treatment of MH. We recommend that appropriate anesthetic monitoring equipment should be strictly applied and a stock of initial dose of dantrolene (6 vials) should be kept, which are necessary for early diagnosis and treatment of MH.
恶性高热(MH)是一种具有高死亡率的高代谢紊乱疾病。静脉注射丹曲林是其特效治疗方法。然而,降低死亡率的唯一方法是早期检测和适当治疗。因此,正确监测和方便获取丹曲林对于降低MH的死亡率至关重要。本研究旨在评估台湾地区医院对MH的预防和治疗能力。
本研究选取了台湾地区102家经过认证培训的医院(包括医学中心和地区医院)。设计了一份问卷来评估这些医院处理MH预防和治疗的能力。
共回收66份问卷,回复率为64.7%。调查结果如下:在接受调查的医院中,92%的医院经常使用琥珀酰胆碱进行诱导。在全身麻醉期间进行监测时,66家(100%)医院常规使用脉搏血氧仪,51家(77.3%)医院使用呼气末二氧化碳监测仪,但仅有13家(19.7%)医院常规监测连续体温。23家(34.9%)医院储存有6瓶或更多丹曲林可供立即使用,其余43家(65.1%)医院根本没有丹曲林库存。在这43家医院中,25家(58.1%)依赖其他医院供应丹曲林,从其他医院获取丹曲林所需时间为70.7±34.7分钟。在过去十年中,17家(25.8%)医院发生了21例MH病例,其中15例成功复苏,6例死亡,死亡率为28.6%。
本研究表明,台湾地区一些医院术中(麻醉)监测不足,且没有储备丹曲林用于立即治疗MH。我们建议应严格应用适当的麻醉监测设备,并储备初始剂量的丹曲林(6瓶),这对于MH的早期诊断和治疗是必要的。